Nektar Therapeutics (NASDAQ: NKTR) net income
Nektar Therapeutics reported a net loss of $164.1m for fiscal 2025; in fiscal 2024 it reported a net loss of $119.0m. Earnings per share were −$9.73.
Nektar Therapeutics's best year of the last 10 was fiscal 2018. It reported a loss in 9 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$164.1m | — | −297.1% | −$9.73 |
| 2024 | −$119.0m | — | −120.9% | −$0.58 |
| 2023 | −$276.1m | — | −306.3% | −$1.45 |
| 2022 | −$368.2m | — | −400.0% | −$1.97 |
| 2021 | −$523.8m | — | −514.0% | −$2.86 |
| 2020 | −$444.4m | — | −290.6% | −$2.49 |
| 2019 | −$440.7m | −164.7% | −384.5% | −$2.52 |
| 2018 | $681.3m | — | 57.1% | $4.02 |
| 2017 | −$96.7m | — | −31.4% | −$0.62 |
| 2016 | −$153.5m | — | −92.8% | −$1.10 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Nektar Therapeutics net income compared with its sector
By net income for its latest fiscal year, Nektar Therapeutics ranks 392nd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Nektar Therapeutics, −297.1%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 390th | Dianthus Therapeutics | −$162.3m | −1,007.1% |
| 391st | Olema Pharmaceuticals | −$162.5m | — |
| 392nd | Nektar Therapeutics | −$164.1m | −297.1% |
| 393rd | Larimar Therapeutics | −$165.7m | — |
| 394th | Arrivent Biopharma | −$166.3m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Nektar Therapeutics
- How much did Nektar Therapeutics earn in fiscal 2025?
- Nektar Therapeutics reported a net loss of $164.1m for fiscal 2025. In fiscal 2024 it reported a net loss of $119.0m.
- What are the earnings per share of Nektar Therapeutics?
- They were −$9.73 in fiscal 2025, compared with −$0.58 in fiscal 2024.
- What was the most profitable year for Nektar Therapeutics?
- Of its last 10 fiscal years, fiscal 2018, with $681.3m.
- Where does Nektar Therapeutics rank in its sector by net income?
- It ranks 392nd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Nektar Therapeutics come from?
- From the annual report (Form 10-K) that Nektar Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Nektar Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Nektar Therapeutics: the Nektar Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.